Horizon doses first participant in Phase I gout therapy trial

The Phase I trial will evaluate the pharmacokinetics, tolerability, pharmacodynamics, and safety of HZN-457.

The Metaverse: Macroeconomic trends

Free Report The Metaverse is becoming a reality – adapt to meet it Although the term resists single definition, the…

Biosimilars hit a turning point as they expand outside oncology

Biosimilar drugs are biological medicines that are extremely similar to another biological medicine that has already been licensed for use.

Health Canada grants CTA authorisation for QurAlis’ ALS therapy

Assessing the safety and tolerability of varying doses of QRL-201 in ALS patients is the primary objective of the trial.